Nureca FY26: A ₹147 Cr Top Line, a ₹2 Cr Bottom Line, and a 110x Multiple Doing the Heavy Lifting

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Nureca closed FY26 with revenue of ₹146.96 crore, up 34% on the year — the fastest top-line growth the company has posted since the pandemic boom faded. Net profit landed at ₹2.08 crore. Put those two numbers side by side and the shape of the business comes into focus: a ₹147 crore company that converted roughly 1.4% of sales into profit, and even that thin sliver leaned on ₹8.1 crore of other income against an operating profit that rounds to zero.

Then the March quarter arrived and detonated the calm. Q4 FY26 swung to a net loss of ₹6.09 crore, against a ₹2.47 crore profit a year earlier — a 347% reversal. Management attributed the swing to an ₹8.34 crore fair-value loss on investments, booked separately under other expenses per IND AS, per the results filing. The operating business kept selling devices; the treasury book did the damage.

The market, meanwhile, pays 110x earnings for all of this, against an industry multiple near 38x. A balance sheet carrying ₹2.26 crore of debt and ₹41 crore of cash sits underneath a profit-and-loss statement that can’t decide whether it’s turning around or treading water.

Does a 34% revenue jump matter when the bottom line is a rounding error plus other income? That tension runs through the whole FY26 record.

2. Introduction

Nureca Limited, incorporated in 2016 and listed since 2021, sells home healthcare and wellness products — blood-pressure monitors, nebulizers, massagers, thermometers, smart scales — overwhelmingly online, under the Dr Trust, Dr Physio and Trumom brands. More than 90% of revenue comes from online sales, making it a genuinely digital-first operator in a category that still smells of pharmacy shelves.

FY26 was a year of structural moves rather than quiet operations. The board approved capex of up to ₹100 crore in May 2026 for a plant-and-machinery expansion at Dera Bassi, Punjab, raised to ₹128 crore by a 1 June corrigendum, per the filings. A buyback at ₹330 per share completed in December 2025, extinguishing shares and lifting promoter holding to 68.09%. The finance chair turned over: CFO Naresh Gupta resigned with a last working day of 26 June 2026, and Chander Kant — already the company’s Manager Finance — was promoted to CFO from 27 June, per the board disclosure.

And in June, a promoter family settlement surfaced: shares held by Aryan and Payal Goyal are to transfer to Saurabh Goyal, with Aryan to resign as CEO and director, per the 20 June announcement. That arrives less than a month after the same board approved Aryan’s reappointment as Whole-Time Director and CEO from 2027. The record holds both.

3. Business Model: WTF Do They Even Do?

Nureca is, in plain terms, a healthcare gadget brand that lives on the internet. It designs and sources devices, slaps the Dr Trust name on them, and moves them through Amazon, Flipkart, its own drtrust.in store, and increasingly the quick-commerce shelves of Blinkit, Swiggy Instamart and Zepto. The company reports 277+ active SKUs and a portfolio spanning chronic-disease monitoring, fitness, orthocare, mother-and-baby, and nutrition.

The model’s selling point is asset-light reach: more than 90% online revenue, no sprawling retail estate, and a brand the company says customers ranked number one in home healthcare. The model’s catch is equally plain — selling commodity electronics-with-a-health-label online is a margin knife-fight, and FY26’s operating profit of essentially zero on ₹147 crore of sales tells that story without commentary.

The newer ambition is Dr Trust 360, a connected-health app that crossed 2.4 million registered users and now bolts on an AI analytics subscription, per the June press release. It’s the company’s attempt to graduate from selling a scale to renting a relationship — to turn a one-time ₹2,000 device sale into recurring software revenue. Whether body-fat trend charts convince Indian households to pay a subscription is the open question; the app is live, the monetisation is young.

There’s also a manufacturing pivot underway. Wholly-owned subsidiary Nureca Technologies began operations in April 2022, makes ten product categories in-house, and is the reason for the ₹128 crore Punjab capex. A digital-first brand is quietly turning into a brand that also owns factories.

Does owning the factory fix a margin problem, or just move it onto the balance sheet?

4. Financials Overview

Figures are consolidated, in ₹ crore. The latest period is the quarter ended March 2026 (Q4 FY26).